Trial Profile
Phase I Study of Romidepsin (ISTODAX) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; Carboplatin; Etoposide; Ifosfamide; Mesna
- Indications T-cell lymphoma
- Focus Adverse reactions
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 28 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 28 Sep 2016 Status changed from recruiting to active, no longer recruiting.